New Formulations of Stimulants: An Update for Clinicians

Area of Science:

• Pharmacology
• Neuroscience
• Clinical Pharmacy

Background:

• Attention-deficit/hyperactivity disorder (ADHD) treatment has evolved significantly.
• A surge in novel stimulant formulations, particularly long-acting ones, has emerged.
• Existing treatments primarily involve amphetamine (AMP) and methylphenidate (MPH).

Purpose of the Study:

• To review advancements in stimulant formulations for ADHD.
• To guide clinicians in selecting appropriate formulations for individualized treatment.
• To highlight the importance of understanding pharmacodynamics, pharmacokinetics, and metabolism for optimizing ADHD therapy.

Main Methods:

• Review of recent literature on stimulant formulations for ADHD.
• Analysis of novel delivery systems including orally dissolving tablets, chewable tablets, extended-release liquids, transdermal patches, and beaded technology.
• Examination of clinical knowledge regarding individual differences in response to AMP and MPH.

Main Results:

• A wide array of new stimulant formulations are now available, enhancing treatment personalization.
• Clinicians have improved ability to individualize ADHD treatment due to formulation diversity and advanced knowledge.
• Pharmacodynamic, pharmacokinetic, and metabolic differences between MPH and AMP are crucial for tailoring treatment in the absence of biomarkers.

Conclusions:

• The increasing variety of stimulant formulations allows for more precise tailoring of ADHD treatment.
• Understanding formulation properties (onset, duration, safety, tolerability) is key for clinical decision-making.
• Clinicians need to be familiar with the spectrum of available AMP and MPH formulations to optimize patient outcomes.